表紙
市場調査レポート

高眼圧症:パイプライン製品の分析

Ocular Hypertension - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 219790
出版日 ページ情報 英文 127 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
高眼圧症:パイプライン製品の分析 Ocular Hypertension - Pipeline Review, H1 2016
出版日: 2016年03月22日 ページ情報: 英文 127 Pages
概要

高眼圧症は、眼内の圧力(眼圧として知られる)が正常だと考えられている範囲(たいてい21mm Hg以上と定義される)を超えた時に起こります。症状には目の痛みまたは充血、虹視症、および頭痛などがあります。素因には、人種、家族歴、近視および糖尿病が含まれます。治療には手術および特定の薬剤が使用されます。

当レポートでは、世界における高眼圧症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

高眼圧症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

高眼圧症:企業で開発中の治療薬

高眼圧症:大学/機関で研究中の治療薬

高眼圧症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

高眼圧症:企業で開発中の製品

高眼圧症:大学/機関で研究中の製品

高眼圧症の治療薬開発に従事している企業

  • Aerie Pharmaceuticals, Inc.
  • Allergan Plc
  • Amakem NV
  • 旭化成ファーマ
  • Bausch & Lomb Incorporated
  • Can-Fite BioPharma Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Inotek Pharmaceuticals Corporation
  • Merck & Co., Inc.
  • NicOx S.A.
  • Ocular Therapeutix, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • 大塚ホールディングス
  • Sanofi
  • 参天製薬
  • 千寿製薬
  • Sylentis S.A.

高眼圧症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (bimatoprost + brimonidine tartrate)
  • (carteolol hydrochloride + latanoprost)
  • (dorzolamide hydrochloride + latanoprost)
  • (latanoprost + trabodenoson)
  • (tafluprost + timolol maleate)
  • AMA-0076
  • AR-13324
  • ATS-8535
  • bamosiran
  • bimatoprost SR
  • DE-117
  • 遺伝子療法
  • latanoprost
  • latanoprost
  • latanoprost SR
  • latanoprost SR
  • latanoprostene bunod
  • lomerizine
  • NCX-470
  • NCX-667
  • ONO-9054
  • OPA-6566
  • piclidenoson
  • RO-5093151
  • SAR-366234
  • SNJ-1656
  • tafluprost
  • trabodenoson
  • travoprost SR

高眼圧症:最近のパイプライン動向

高眼圧症:休止中のプロジェクト

高眼圧症:開発が中止された製品

高眼圧症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7715IDB

Summary

Global Markets Direct's, 'Ocular Hypertension - Pipeline Review, H1 2016', provides an overview of the Ocular Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
  • The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ocular Hypertension Overview
  • Therapeutics Development
    • Pipeline Products for Ocular Hypertension - Overview
    • Pipeline Products for Ocular Hypertension - Comparative Analysis
  • Ocular Hypertension - Therapeutics under Development by Companies
  • Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes
  • Ocular Hypertension - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Ocular Hypertension - Products under Development by Companies
  • Ocular Hypertension - Products under Investigation by Universities/Institutes
  • Ocular Hypertension - Companies Involved in Therapeutics Development
    • Aerie Pharmaceuticals, Inc.
    • Allergan Plc
    • Amakem NV
    • Asahi Kasei Pharma Corp.
    • Bausch & Lomb Incorporated
    • Can-Fite BioPharma Ltd.
    • D. Western Therapeutics Institute, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Inotek Pharmaceuticals Corporation
    • Kowa Company, Ltd.
    • Lee's Pharmaceutical Holdings Limited
    • NicOx S.A.
    • Ocular Therapeutix, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Otsuka Holdings Co., Ltd.
    • pSivida Corp.
    • Sanofi
    • Santen Pharmaceutical Co., Ltd.
    • Senju Pharmaceutical Co., Ltd.
    • Sylentis S.A.U.
    • ViSci Ltd.
  • Ocular Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (carteolol hydrochloride + latanoprost) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (dorzolamide hydrochloride + latanoprost) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (latanoprost + netarsudil mesylate) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (latanoprost + trabodenoson) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (tafluprost + timolol maleate) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMA-0076 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATS-8535 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bamosiran - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimatoprost - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimatoprost SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DE-117 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • H-1129 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • latanoprostene bunod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levobetaxolol hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NCX-470 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NCX-667 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • netarsudil mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONO-9054 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPA-6566 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • piclidenoson - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-4929 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ripasudil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RO-5093151 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-366234 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SNJ-1656 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trabodenoson - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • travoprost SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ocular Hypertension - Recent Pipeline Updates
  • Ocular Hypertension - Dormant Projects
  • Ocular Hypertension - Discontinued Products
  • Ocular Hypertension - Product Development Milestones
    • Featured News & Press Releases
      • Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting
      • Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week
      • Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2
      • Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension
      • Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial
      • Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
      • Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa
      • Sep 22, 2015: Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO (latanoprostene bunod)
      • Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan
      • Sep 16, 2015: Aerie Pharmaceuticals Reports Positive Rhopressa Phase 3 Efficacy Results
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ocular Hypertension, H1 2016
  • Number of Products under Development for Ocular Hypertension - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H1 2016
  • Ocular Hypertension - Pipeline by Allergan Plc, H1 2016
  • Ocular Hypertension - Pipeline by Amakem NV, H1 2016
  • Ocular Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2016
  • Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H1 2016
  • Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H1 2016
  • Ocular Hypertension - Pipeline by D. Western Therapeutics Institute, Inc., H1 2016
  • Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H1 2016
  • Ocular Hypertension - Pipeline by Kowa Company, Ltd., H1 2016
  • Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Ocular Hypertension - Pipeline by NicOx S.A., H1 2016
  • Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H1 2016
  • Ocular Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Ocular Hypertension - Pipeline by pSivida Corp., H1 2016
  • Ocular Hypertension - Pipeline by Sanofi, H1 2016
  • Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
  • Ocular Hypertension - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016
  • Ocular Hypertension - Pipeline by Sylentis S.A.U., H1 2016
  • Ocular Hypertension - Pipeline by ViSci Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Ocular Hypertension Therapeutics - Recent Pipeline Updates, H1 2016
  • Ocular Hypertension - Dormant Projects, H1 2016
  • Ocular Hypertension - Dormant Projects (Contd..1), H1 2016
  • Ocular Hypertension - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Ocular Hypertension, H1 2016
  • Number of Products under Development for Ocular Hypertension - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top